First preclinical SPECT/CT imaging and biodistribution of [165Er]ErCl3 and [165Er]Er-PSMA-617
2024

First Preclinical Imaging of Erbium-165 for Cancer Treatment

Sample size: 4 publication 10 minutes Evidence: moderate

Author Information

Author(s): Saeedi Saghez Behrad, Rodríguez-Rodríguez Cristina, Esquinas Pedro Luis, Merkens Helen, Bénard François, Radchenko Valery

Primary Institution: TRIUMF, University of British Columbia, BC Cancer Research Institute

Hypothesis

Can Erbium-165 be effectively used for SPECT imaging and biodistribution studies in cancer treatment?

Conclusion

The study successfully demonstrated the use of Erbium-165 for preclinical SPECT imaging and its potential as a tool for evaluating targeted radiopharmaceuticals.

Supporting Evidence

  • Erbium-165 was produced with high yield and purity using a cyclotron.
  • The radioligand [165Er]Er-PSMA-617 showed high stability in serum.
  • SPECT imaging demonstrated good tumor uptake in preclinical models.
  • Quantitative accuracy of SPECT images was validated against ex vivo biodistribution.

Takeaway

This study shows that a special type of Erbium can help doctors see tumors better using special imaging techniques, which could help treat cancer.

Methodology

The study involved producing Erbium-165, synthesizing radioligands, and conducting SPECT imaging and biodistribution studies in tumor-bearing mice.

Limitations

The study is preclinical and results may not directly translate to human applications.

Participant Demographics

Male NRG mice bearing LNCaP tumors were used for the studies.

Statistical Information

Confidence Interval

95%

Digital Object Identifier (DOI)

10.1186/s41181-024-00312-9

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication